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Background: In this study, we used functional proteomics to determine the molecular characteristics of residual triple
receptor-negative breast cancer (TNBC) patients after neoadjuvant systemic chemotherapy (NCT) and their relationship
with patient outcomes in order to identify potential targets for therapy.
Patients and methods: Protein was extracted from 54 residual TNBCs, and 76 proteins related to breast cancer
signaling were measured by reverse phase protein arrays (RPPAs). Univariable and multivariable Cox proportional hazard
models were ﬁtted for each protein. Survival outcomes were estimated by the Kaplan–Meier product limit method.
Training and cross validation were carried out. The coefﬁcients estimated from the multivariable Cox model were used to
calculate a risk score (RS) for each sample.
Results:Multivariable analysis using the top 25 proteins from univariable analysis at a false discovery rate (FDR) of 0.3
showed that AKT, IGFBP2, LKB1, S6 and Stathmin were predictors of recurrence-free survival (RFS). The cross-
validation model was reproducible. The RS model calculated based on the multivariable analysis was
−1.1086 × AKT + 0.2501 × IGFBP2 − 0.6745 × LKB1+1.0692 × S6 + 1.4086 × stathmin with a corresponding area under
the curve, AUC = 0.856. The RS was an independent predictor of RFS (HR = 3.28, 95%CI = 2.07–5.20, P < 0.001).
Conclusions:We found a ﬁve-protein model that independently predicted RFS risk in patients with residual TNBC
disease. The PI3 K pathway may represent potential therapeutic targets in this resistant disease.
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introduction
Triple receptor-negative breast cancers (TNBCs) are
characterized by the lack of expression of estrogen receptor
(ER), progesterone receptor (PR) and HER2, comprising ∼12%
to 17% of invasive breast cancers [1]. Patients with TNBCs have
relatively poor outcomes and are not eligible to be treated with
endocrine therapies or anti-HER2 targeted therapies [1].
Neoadjuvant (preoperative) or adjuvant systemic chemotherapy
has been shown to improve survival in early disease. Pathologic
complete response (pCR) after neoadjuvant chemotherapy
(NCT) is known as a surrogate marker for long-term survival in
TNBCs [2]. Patients with TNBCs can attain pCR rates of 30%–
40%; however, patients with residual disease are at greater risk of
relapse with dismal outcomes compared with other subtypes of
breast cancer [3]. Despite the signiﬁcant impact of residual
breast cancer after NCT on outcomes, no standard and more
importantly effective therapy exists for this population.
Therefore, there is a critical need for better understanding the
molecular characteristics of such resistant tumors, and to
identify novel targets that can be pursued for a more effective,
personalized intervention to improve outcome.
To have a more precise assessment of the consequences of
residual disease, investigators at our institution developed the
residual cancer burden (RCB) as a continuous index combining
pathologic measurements of the primary tumor and nodal
metastases, and tested it as an independent predictor of distant
relapse-free survival (DRFS) [4]. We and other investigators
previously have shown the utility of reverse phase protein arrays
(RPPAs) as a high-throughput platform to identify protein
biomarkers [5].
In this study, we used RPPAs to determine the molecular
characteristics of residual TNBC patients after NCT and their
relationship with patient outcomes in order to identify potential
targets for therapy.
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patients andmethods
We obtained tumors from 54 patients diagnosed with primary TNBC and
treated uniformly with taxane and anthracycline-based NCT at MD
Anderson Cancer Center (see Supplementary File 1, available at Annals of
Oncology online, for complete patient and methods section). RCB was
calculated [5]. The Institutional Review Board approved the laboratory
protocol and the waiver of informed consent for all included cases.
Protein lysates were arrayed and probed with 76 validated primary
antibodies (supplementary Table S1, available at Annals of Oncology online)
focused on markers currently used for breast cancer classiﬁcation, treatment
decision (ER, PR, HER2), targets implicated in breast cancer signaling and
targets implicated in the signaling of other cancer lineages.
As the ﬁrst exploratory analysis, we carried out unsupervised hierarchical
clustering, using all 76 proteins. To identify proteins most related to survival,
we carried out univariable Cox analysis as the ﬁrst screening step, and
selected the top 25 predictors from the univariable Cox analysis
corresponding to a multiplicity FDR adjustment threshold of 0.3
(supplementary Table S2, available at Annals of Oncology online). Next, we
used CoxBoost to construct a multivariable protein-marker of ﬁve proteins
(AKT, IGFBP2, LKB1, S6 and Stathmin) (Figure 1A). We then developed a
risk score (RS) for each patient, which is the sum of the estimated
coefﬁcients from the ﬁve-protein multivariable CoxBoost model multiplied
by their expression. To assess the robustness of the ﬁve selected proteins, a
‘leave-one-out’ cross-validation approach was employed.
results
Fifty-four patients with residual TNBC were included. Patient
and tumor characteristics are listed in Table 1. The median age
was 52 years (range 27–73). Most patients were Caucasians
(44.4%) and African Americans (42.6%). Most patients had
baseline clinical stage III disease (64.8%) and high nuclear grade
(94.4%).
At a median follow-up of 24 months (range 7–145 months),
there were 36 (66.7%) recurrences. The median RFS was 33
months (range 1–145 months). No clinical factor was
signiﬁcantly correlated with RFS in univariable analyses as
shown in supplementary Table S4, available at Annals of
Oncology online.
unsupervised global clustering
Unsupervised clustering of the 54 residual TNBC samples
and 76 proteins split tumors into two groups. However, the
Figure 1. (A) Clustering into green and red groups depending on the expression levels of AKT, IGFBP2, LKB1, S6 and stathmin 54 residual triple-negative
breast cancers (TNBCs). (B) Multivariable Cox proportional hazard model and calculated risk score (RS). (C) Optimal cut-off point at 1.457 (sensitivity versus
1-speciﬁcity for the RS in all 54 cases. (D) Receiving operating curve of the RS model (AUC = 0.856).
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Kaplan–Meier plot shows that these two groups had no
signiﬁcant difference in RFS, (P = 0.471) (supplementary
Figure S1, available at Annals of Oncology online).
biomarker identiﬁcation
Twenty-ﬁve proteins out of 76 had a false discovery rate (FDR)
of 0.3. The univariable analysis results are presented in
supplementary Table S2, available at Annals of Oncology online.
Multivariable analysis implemented with CoxBoost showed that
5 out of the 25 proteins AKT, IGFBP2, LKB1, S6 and Stathmin
were predictors for RFS. After hierarchical clustering of all 54
tumors with the ﬁve proteins, tumors split into two distinct
groups (Figure 1A). We then deﬁned the RS for each patient as
the estimated coefﬁcients from the ﬁve-protein multivariable
CoxBoost model multiplied by their expression
(RS = −1.1086 × AKT + 0.2501 × IGFBP2 − 0.6745 ×
LKB1 + 1.0692× S6 + 1.4086 × stathmin). An optimal cut-off
point (1.457) (Figure 1B) was obtained for the RS and
corresponded to the value that simultaneously optimized
sensitivity and speciﬁcity (Figure 1C), and the resulting area
under the receiving operating curve was calculated to be 0.856
(Figure 1D).
risk score model for recurrence-free survival
The RS was applied to all patients, and they were classiﬁed as
high and low risk of relapse with signiﬁcantly different 3-year
RFS estimates (7.14%, 95% CI = 1.27–40.1% versus 48.4%, 95%
CI = 32.3–72.6%, P = 0.001) (Table 2, Figure 2A). The RS was
then applied to the leave-one-out cross-validation group and
patients at a high and a low risk of recurrence showed
signiﬁcant differences in 3-year RFS estimates (P = 0.037)
(Table 2, Figure 2B).
The ﬁnal multivariable Cox proportional hazard model
conﬁrmed that the RS was an independent predictor of RFS
(HR = 3.28, 95% CI = 2.07–5.20, P < 0.001) after adjustment for
other known signiﬁcant patient and disease characteristics,
including clinical stage at diagnosis, nuclear grade and RCB (a
measurement of the volume of the residual disease at the time of
surgery) (Table 3).
discussion
This biomarker identiﬁcation study, using 76 antibodies to
proteins related to breast cancer signaling for RPPA, showed
that AKT, IGFBP2, LKB1, S6 and stathmin were predictors of
RFS in 54 patients with residual TNBC after NCT. The obtained
RS model based on the ﬁve identiﬁed proteins was found to be
reproducible on leave-one-out cross validation. Multivariable
analysis incorporating known important clinical and
pathological factors of prognosis suggested that the RS was an
independent predictor of RFS.
In breast malignancy, residual disease after NCT with
anthracyclines and taxanes is considered to be resistant to
standard chemotherapy; however, no further systemic therapy is
indicated as no effective drugs have yet been identiﬁed. To our
knowledge, our study is the ﬁrst approach focusing on
discovering molecular targets in these chemo-resistant residual
Table 1. Patient and tumor characteristics
Characteristic Number Percentage
Age (years)
≤50 26 48.1
>50 28 51.9
Menopausal status
Pre-menopause 19 35.2
Peri-/postmenopause 35 64.8
Ethnicity
White 24 44.4
African American 23 42.6
Hispanic 6 11.1
Asian 1 1.9
Baseline stage
I and II 19 35.2
III 35 64.8
Pathologic stage
I and II 22 40.8
III 32 59.2
Nuclear grade
2 3 5.6
3 51 94.4
Residual cancer burden (RCB)
II 13 24.1
III 41 75.9
Lymphovascular space invasion
Yes 33 61.1
No 21 38.9
Surgical therapy
Breast-conserving therapy 10 18.5
Mastectomy 44 81.5
Table 2. Recurrence-free survival (RFS) estimates by risk group in training and cross-validation
N N Events Median RFS (range)
in months
3-year estimate 95% conﬁdence
interval
P value
Training
All
High-risk clustering 24 22 11 (4–91) 7.14% (1.27%, 40.1%)
Low-risk clustering 30 14 20 (0–145) 48.4% (32.3%, 72.6%) 0.0014
Cross-validation
All
High-risk clustering 26 21 12 (4–91) 13.7% (4.3%, 43.5%)
Low-risk clustering 28 15 20 (0–145) 43.3% (27.5%, 68.1%) 0.0367
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TNBCs based on a high-throughput protein array technique in
the targeted therapy era.
Stathmin is a ubiquitous cytosolic phosphoprotein and a key
regulator of cell division due to its depolymerization of
microtubules in a phosphorylation-dependent manner. Its ability
to remodel microtubule networks through tubulin
polymerization indicates a role for stathmin in tumor cell
migration and invasion [6]. Constitutive activation and
overexpression of stathmin expression have been associated with
a variety of human cancers, including breast, lung, gastric,
ovarian, cervical, prostate, urothelial, hepatocellular and
colorectal [7, 8]. In breast cancer cell lines, stathmin
overexpression has been associated with reduced taxane
sensitivity and increased resistance to taxane-based
chemotherapy [9]. In patients with breast cancer, overexpression
of stathmin messenger RNA has been correlated with high
mitotic index, loss of hormone receptors and poor prognosis
[10]. A study using traditional immunohistochemistry evaluated
stathmin protein expression as a surrogate marker for a PTEN
gene expression signature [11]. Investigators found that stathmin
IHC staining scores were signiﬁcantly higher in PTEN-negative
tumors than in PTEN-positive tumors (P = 0.005), indicating
that loss of the tumor suppressor PTEN, and subsequent
activation of PI3 K signaling were associated with increased
stathmin expression. In addition, high-stathmin-expressing
patients experienced signiﬁcantly worse DRFS than
low-stathmin-expressing patients [11].
Insulin-like growth factor (IGF) binding proteins (IGFBP)
modulate interactions of the IGF ligand with the IGF-I receptor.
Studies on IGFBP2 expression in breast cancer tissue are still
limited in number. High IGFBP2 concentrations in blood or
malignant cells and tissues have shown to be predictive of poor
prognosis in many malignancies including colon, lung, ovary,
prostate and other tumors [12–14]. The largest study on the
prognostic role of IGFBP2 included tumor specimens from
4186 patients with breast cancer [12]. In this study, IGFBP2 was
not prognostic in patients with ER-positive disease, but it was
associated with a trend to worse breast cancer disease-speciﬁc
survival in patients with ER-negative disease, (P = 0.068), which
is consistent with our study that showed IGFBP2 as a poor
prognostic factor. These results imply the possibility of IGFBP2
as a potential novel target for patients with residual TNBCs.
The ribosomal protein S6 (S6 kinase) represents an extensively
studied effector of the TORC1 [TOR (target of rapamycin)
complex 1], which possesses important roles in cellular and
organismal physiology. TORC1 functions as an environmental
sensor by integrating signals derived from diverse environmental
cues to promote anabolic and inhibit catabolic cellular functions.
mTORC1 (mammalian TORC1) phosphorylates and activates
S6K1 and S6K2. The mTORC1-S6K1 axis regulates cell
physiology by controlling fundamental cellular processes,
including transcription, translation, protein and lipid synthesis,
cell growth and cell metabolism [15]. Persistent inhibition of
S6K1 has been shown to activate Akt via feedback inhibition of
the PI3 K pathway, wherein S6K1 phosphorylates several sites on
IRS-1 (insulin receptor substrate-1) and inhibits it [16–20]. The
limited therapeutic efﬁcacy of rapamycin and its analogs in some
tumor types has been attributed in part to the activation of AKT
via this negative feedback loop [16–19]. The S6 protein is a
Figure 2. (A) Kaplan–Meier survival curves by risk score (RS). (B) Kaplan–Meier survival curve by RC in leave-one-out cross validation.
Table 3. Multivariable model including the risk score (RS) and residual
cancer burden (RCB)
Variables Hazard
ratio
95% conﬁdence
intervals
P value
Age at diagnosis (continuous) 0.99 0.96–1.01 0.320
Clinical stage (I and II
versus III)
0.60 0.27–1.35 0.219
Nuclear grade (2 versus 3) 4.53 0.89– 22.93 0.068
RCB (continuous) 1.27 0.85–1.90 0.239
RS (continuous) 3.28 2.07–5.20 <0.001
RS only model
RS (continuous) 2.718 1.855–3.988 <0.001
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downstream target of S6K1. The mechanism by which changes in
total protein levels in S6 protein could alter patient outcomes
remains to be determined.
LKB1 is a kinase-activating kinase and a number of LKB1
dependent phosphorylation cascades regulate fundamental
cellular and organismal processes in at least metabolism,
polarity, cytoskeleton organization and proliferation. The
characterized substrate of LKB1 is adenosine monophosphate-
activated protein kinase, which is the master regulator of cellular
and organismal metabolism, providing a putative downstream
pathway to LKB1-mediated tumor suppression [20]. Indeed, a
high level of PI3 K activity can improve bioenergetics by
increasing nutrient uptake as well as through other mechanisms.
All together, these results suggest that residual TNBC is
characterized by activation of components of the PI3 K
pathway. Further, other forms of deregulation and aberrations
of this pathway have been implicated not only in breast cancer
development and progression [21], but also in resistance to
targeted therapies directed to tyrosine kinase receptors and
hormone receptors [22–25]. As a result, multiple drugs
targeting the PI3 K pathway are in early clinical trials as mono
or combination therapies in breast cancer including TNBC [26].
Our study had limitations, the small sample size only allowed
us to conduct leave-one-out cross-validation rather than formal
validation on an independent set. Nevertheless, the RS model of
ﬁve proteins that predicted outcomes in patients with residual
TNBC warrants further testing to evaluate its prognostic potential
and clinical applicability. In conclusion, we found a ﬁve-protein
model that independently predicted RFS risk in patients with
residual TNBC disease after NCT. The RS may have value in
stratifying patients based on their risk of relapse, providing
potential targets for novel agents to treat this resistant disease.
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